Symptomatic women experience long waits for endometrial cancer diagnosis and treatment in Brazil

The aim of this study was to assess the elapsed time for symptomatic women with endometrial carcinoma to achieve diagnosis and treatment and its impact on staging and survival. A cohort study was carried out with 430 women divided into in two groups: “Type I” (n = 289, endometrioid carcinoma grade 1 or 2); “Type II” (n = 141, nonendometrioid, endometrioid carcinoma grade 3, or carcinosarcoma). Clinical information, diagnostic methods, histology, staging, and time elapsed between symptoms-diagnosis-treatment were considered. Descriptive, survival, and regression analyses were performed. The symptom-to-diagnosis interval was 284 and 249 days in Types I and II (p = 0.014), with only 30% getting a diagnosis within 90 days. The diagnosis-to-treatment interval was shorter for Type II (100 vs. 123 days for Type I; p = 0.001). Only 12.5% of Type I and 22.7% of Type II started treatment within 60 days after diagnosis. There was no association between symptom-to-diagnosis interval and staging (p = 0.377). The symptom-to-treatment interval did not change the overall survival for Type I and had a paradoxical effect for Type II, with greater overall survival associated with a longer elapsed time (p = 0.003). Symptomatic Brazilian women with endometrial carcinomas showed very long wait times for diagnosis and treatment, and less than 23% started treatment within the regulatory period of 60 days. This critical situation does not exhibit any clear effect on cancer staging or overall survival, possibly counterbalanced by the faster care of patients with a poor prognosis, such as those with Type II endometrial carcinomas.

Endometrial carcinoma; Staging; Services accessibility; Time-to-treat; Survival

[1] Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021; 71: 209–249.

[2] Instituto Nacional de Câncer José Alencar Gomes da Silva (INCA). Estimativa 2020: Incidencia de Cancer no Brasil. 2020. Available at: https://www.inca.gov.br/sites/ufu.sti.inca.local/files//media/document//estimativa-2020-incidencia-de-cancer-no-brasil.pdf (Accessed: 03 July 2021).

[3] Jamison PM, Altekruse SF, Chang JT, Zahn J, Lee R, Noone A, et al. Site-specific factors for cancer of the corpus uteri from SEER registries: collaborative stage data collection system, version 1 and version 2. Cancer. 2014; 120: 3836–3845.

[4] Plentz TBSF, Candido EC, Dias LF, Toledo MCS, Vale DB, Teixeira JC. Diagnosis, treatment and survival of uterine sarcoma: a retrospective cohort study of 122 cases. Molecular and Clinical Oncology. 2020; 13: 81.

[5] Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecologic Oncology. 1983; 15: 10–17.

[6] Felix AS, Yang HP, Bell DW, Sherman ME. Epidemiology of endometrial carcinoma: etiologic importance of hormonal and metabolic influences. Advances in Experimental Medicine and Biology. 2017; 294: 3–46.

[7] Amant F, Mirza MR, Koskas M, Creutzberg CL. Cancer of the corpus uteri. International Journal of Gynecology & Obstetrics. 2015; 131: S96–S104.

[8] Yasa C, Dural O, Bastu E, Ugurlucan FG, Nehir A, İyibozkurt AC. Eval-uation of the diagnostic role of transvaginal ultrasound measurements of endometrial thickness to detect endometrial malignancy in asymptomatic postmenopausal women. Archives of Gynecology and Obstetrics. 2016; 294: 311–316.

[9] Candido EC, Veiga Junior NN, Minari MP, Toledo MCS, Yela DA, Teixeira JC. Malignant uterine neoplasms attended at a brazilian regional hospital: 16-years profile and time elapsed for diagnosis and treatment. Revista Brasileira De Ginecologia E ObstetríCia. 2021; 43: 137–144. (In Portuguese)

[10] Brasil. Law no 12.732, November 22, 2012. The 60-Day Cancer Treatment Act. 2012. Available at: https://www.planalto.gov.br/ccivil_03/_ato2011-2014/2012/lei/l12732.htm (Accessed: 21 July 2021).

[11] Menczer J, Krissi H, Chetrit A, Gaylor J, Lerner L, Ben-Baruch G, et al. The effect of diagnosis and treatment delay on prognostic factors and survival in endometrial carcinoma. American Journal of Obstetrics and Gynecology. 1995; 173: 774–778.

[12] Matsuo K, Opper NR, Ciccone MA, Garcia J, Tierney KE, Baba T, et al. Time interval between endometrial biopsy and surgical staging for type I endometrial cancer: association between tumor characteristics and survival outcome. Obstetrics & Gynecology. 2015; 125: 424–433.

[13] AlHilli MM, Elson P, Rybicki L, Khorana AA, Rose PG. Time to surgery and its impact on survival in patients with endometrial cancer: a national cancer database study. Gynecologic Oncology. 2019; 153: 511–516.

[14] Mitric C, Matanes E, Wissing M, Amajoud Z, Abitbol J, Yasmeen A, et al. The impact of wait times on oncological outcome in high‐risk patients with endometrial cancer. Journal of Surgical Oncology. 2020; 122: 306–314.

[15] Word Health Organization. CID-O—Classificaçao Internacional de Doenças para Oncologia. 3rd edn. Editora da Universidade de São Paulo: São Paulo, Brazil. 2005.

[16] Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO Classification of Tumours of Female Reproductive Organs. In WHO Classification of Tumours (pp. 135–147). 4th edn. International Agency for Research on Cancer: Lyon, France. 2014.

[17] FIGO Committee on Gynecologic Oncology. FIGO staging for carcinoma of the vulva, cervix, and corpus uteri. International Journal of Gynecology & Obstetrics. 2014; 125: 97–98.

[18] Crosbie EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, Powell ME, Singh N. Endometrial cancer. The Lancet. 2022; 399: 1412–1428.

[19] Paulino E, Nogueira-Rodrigues A, Goss PE, Faroni L, Guitmann G, Strasser-Weippl K, et al. Endometrial cancer in Brazil: preparing for the rising incidence. Revista Brasileira De Ginecologia E ObstetríCia. 2018; 40: 577–579. (In Portuguese)

[20] Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram‐Baptiste D, Saslow D, et al. Cancer screening in the United States, 2019: a review of current American Cancer Society guidelines and current issues in cancer screening. CA: A Cancer Journal for Clinicians. 2019; 69: 184–210.

[21] Maringe C, Spicer J, Morris M, Purushotham A, Nolte E, Sullivan R, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. The Lancet Oncology. 2020; 21: 1023–1034.